Recruiting Pulmonary Embolism Studies in Portland
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
The purpose of this study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the possible treatment of severe alopecia areata. Alopecia areata is a condition that...
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Wheth...
Omega-3 Fatty Acid Lipidomics in Diabetes Peripheral Neuropathy
Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes, affecting about 50% of patients with diabetes and leading to severe morbidity, poor quality of life, high mort...
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT). Participants with suspecte...
A Phase 3 Study of Ersodetug in Patients With Tumor-Associated Hyperinsulinism
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug for treatment of hypoglycemia in patients with Tumor-Associated Hyperinsulinism (tHI)....
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyop...
Ruxolitinib in Treating Patients with Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders....
About Pulmonary Embolism Clinical Trials in Portland
Pulmonary embolism (PE) is a blockage of an artery in the lungs, usually caused by blood clots that travel from the deep veins of the legs. It can be life-threatening and requires immediate medical attention. Treatment includes anticoagulants and in severe cases, thrombolytic therapy.
There are currently 7 pulmonary embolism clinical trials recruiting participants in Portland, ME. These studies are seeking a combined 623 participants. Research is being sponsored by Pfizer, Alessandro Doria, University of Iowa and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Pulmonary Embolism Clinical Trials in Portland — FAQ
Are there pulmonary embolism clinical trials in Portland?
Yes, there are 7 pulmonary embolism clinical trials currently recruiting in Portland, ME. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Portland?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Portland research site will contact you about next steps.
Are clinical trials in Portland free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Portland studies also compensate for your time and travel.
What pulmonary embolism treatments are being tested?
The 7 active trials in Portland are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary embolism.
Data updated March 2, 2026 from ClinicalTrials.gov